163 related articles for article (PubMed ID: 38437852)
1. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.
Nguyen Y; Nocturne G; Henry J; Ng WF; Belkhir R; Desmoulins F; Bergé E; Morel J; Perdriger A; Dernis E; Devauchelle-Pensec V; Sène D; Dieudé P; Couderc M; Fauchais AL; Larroche C; Vittecoq O; Salliot C; Hachulla E; Le Guern V; Gottenberg JE; Mariette X; Seror R
Lancet Rheumatol; 2024 Apr; 6(4):e216-e225. PubMed ID: 38437852
[TBL] [Abstract][Full Text] [Related]
2. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
3. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
4. Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature.
Pucino V; Turner JD; Nayar S; Kollert F; Rauz S; Richards A; Higham J; Poveda-Gallego A; Bowman SJ; Barone F; Fisher BA
RMD Open; 2022 May; 8(1):. PubMed ID: 35589331
[TBL] [Abstract][Full Text] [Related]
5. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
[TBL] [Abstract][Full Text] [Related]
6. Symptom-Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance.
McCoy SS; Woodham M; Bartels CM; Saldanha IJ; Bunya VY; Maerz N; Akpek EK; Makara MA; Baer AN
Arthritis Rheumatol; 2022 Sep; 74(9):1569-1579. PubMed ID: 35594474
[TBL] [Abstract][Full Text] [Related]
7. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
8. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
[TBL] [Abstract][Full Text] [Related]
9. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
11. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.
Seror R; Ravaud P; Mariette X; Bootsma H; Theander E; Hansen A; Ramos-Casals M; Dörner T; Bombardieri S; Hachulla E; Brun JG; Kruize AA; Praprotnik S; Tomsic M; Gottenberg JE; Devauchelle V; Devita S; Vollenweider C; Mandl T; Tzioufas A; Carsons S; Saraux A; Sutcliffe N; Vitali C; Bowman SJ;
Ann Rheum Dis; 2011 Jun; 70(6):968-72. PubMed ID: 21345815
[TBL] [Abstract][Full Text] [Related]
12. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
14. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
[TBL] [Abstract][Full Text] [Related]
15. [Contemporary diagnostics of the primary Sjögren's syndrome].
Parada-Turska J
Wiad Lek; 2016; 69(4):680-685. PubMed ID: 27941210
[TBL] [Abstract][Full Text] [Related]
16. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
Cho HJ; Yoo JJ; Yun CY; Kang EH; Lee HJ; Hyon JY; Song YW; Lee YJ
Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the EULAR Sjögren's Syndrome Patient-Reported Index in primary Sjögren's syndrome.
Sandoval-Flores MG; Chan-Campos I; Hernández-Molina G
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):153-158. PubMed ID: 34128801
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
19. Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren's syndrome: An exploratory cross-sectional study.
Omair MA; AlQahtani BS; AlHamad EH; Tashkandy YA; Othman NS; AlShahrani KA; Paramasivam MP; AlEnzi F; Halwani R; Daghestani MH
Saudi Med J; 2021 Apr; 42(4):405-410. PubMed ID: 33795496
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.
Gottenberg JE; Seror R; Miceli-Richard C; Benessiano J; Devauchelle-Pensec V; Dieude P; Dubost JJ; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Le Guern V; Morel J; Perdriger A; Puéchal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Nocturne G; Ravaud P; Mariette X
PLoS One; 2013; 8(5):e59868. PubMed ID: 23717383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
